Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $573M | $719M | $1.03B | $1.48B | $1.93B | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
| Revenue growth | — | 25.3% | 43.6% | 43.1% | 30.5% | 27.1% | 18.8% | 24.5% | 11.3% | 15.6% |
| Gross profit | $378M | $492M | $664M | $932M | $1.28B | $1.68B | $1.88B | $2.29B | $2.44B | $2.80B |
| Gross margin | 66.0% | 68.5% | 64.4% | 63.1% | 66.4% | 68.6% | 64.7% | 63.2% | 60.5% | 60.1% |
| Operating income | -$63.9M | -$42.5M | -$186M | $142M | $300M | $266M | $391M | $598M | $600M | $912M |
| Operating margin | -11.1% | -5.9% | -18.1% | 9.6% | 15.5% | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| Net income | -$65.6M | -$50.2M | -$127M | $101M | $550M | $217M | $341M | $542M | $576M | $836M |
| Net margin | -11.4% | -7.0% | -12.3% | 6.8% | 28.5% | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% |
| EPS (diluted) | -$0.78 | -$0.58 | -$1.44 | $1.10 | $1.33 | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $56.2M | $92.0M | $123M | $315M | $476M | $443M | $670M | $749M | $990M | $1.44B |
| Capital expenditures | $55.7M | $66.0M | $67.1M | $180M | $199M | $389M | $365M | $237M | $359M | $364M |
| Free cash flow | $500K | $26.0M | $56.1M | $135M | $277M | $53.3M | $305M | $512M | $631M | $1.08B |
| Share buybacks | $0.00 | $0.00 | $100M | $0.00 | $0.00 | $0.00 | $558M | $689M | $750M | $500M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $94.5M | $442M | $1.14B | $446M | $818M | $1.05B | $642M | $566M | $606M | $918M |
| Total assets | $403M | $904M | $1.92B | $2.40B | $4.29B | $4.93B | $5.39B | $6.26B | $6.48B | $6.34B |
| Total liabilities | $119M | $485M | $1.25B | $1.51B | $2.46B | $2.89B | $3.26B | $4.20B | $4.38B | $3.59B |
| Shareholders' equity | $284M | $419M | $663M | $883M | $1.55B | $2.04B | $2.13B | $2.07B | $2.10B | $2.75B |
| Retained earnings | -$621M | -$672M | -$799M | -$696M | -$78.2M | $139M | $480M | $1.02B | $1.60B | $2.43B |
| Shares (wtd avg diluted) | 84.6M | 86.3M | 88.2M | 92.3M | 420M | 429M | 428M | 426M | 413M | 406M |
Every figure is extracted from DEXCOM INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.